Abstract
Objective Dabrafenib, an inhibitor of mutated BRAF, has significant clinical activity in melanoma patients but is linked to a spectrum of cutaneous to......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
